Last $84.28 USD
Change Today -0.55 / -0.65%
Volume 3.5M
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Snapshot

Open
$83.09
Previous Close
$84.83
Day High
$84.47
Day Low
$83.02
52 Week High
02/24/15 - $88.83
52 Week Low
04/30/14 - $64.64
Market Cap
61.3B
Average Volume 10 Days
4.1M
EPS TTM
$3.35
Shares Outstanding
726.9M
EX-Date
--
P/E TM
25.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for EXPRESS SCRIPTS HOLDING CO (ESRX)

express scripts holding co (ESRX) Details

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. The company’s PBM segment’s services include clinical solutions to enhance health outcomes, such as adherence, case coordination, and personalized medicine; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services for pharmaceutical manufacturers to collect scientific evidence to guide the use of medicines, as well as case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

29,500 Employees
Last Reported Date: 02/23/15
Founded in 1986

express scripts holding co (ESRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
Executive Vice President and General Counsel
Total Annual Compensation: $617.8K
Compensation as of Fiscal Year 2013.

express scripts holding co (ESRX) Key Developments

Express Scripts Seeks Acquisitions

Express Scripts Holding Company (NasdaqGS:ESRX) is seeking acquisitions. Jim Havel, Interim Chief Financial Officer, said, "We're always in the market for acquisitions. We're always in the market to take a look at what can strengthen our platform."

Express Scripts Eliminates 380 Positions; John Parker Retires from the Express Scripts's Board

Express Scripts Holding Co. announced that the company eliminated 380 positions across the country, including 23 in St. Louis. The company also announced longtime board member John Parker retired from the board due to health reasons. Parker has been a board member since 2001.

Express Scripts Holding Company Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year for the Fiscal Year Ending December 31, 2015

Express Scripts Holding Company announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced revenues of $26,312.6 million compared to $25,781.4 million for the same period a year ago. Operating income was $942.8 million compared to $828.8 million for the same period a year ago. Income before income taxes was $830.5 million compared to $726.3 million for the same period a year ago. Net income from continuing operations was $588.7 million compared to $518.3 million for the same period a year ago. Net income was $588.7 million compared to $506.0 million for the same period a year ago. Net income attributable to the company was $581.8 million compared to $501.9 million for the same period a year ago. Diluted earnings per share from continuing operations attributable to the company were $0.79 compared to $0.64 for the same period a year ago. Diluted net earnings attributable to the company were $0.79 compared to $0.63 for the same period a year ago. EBITDA from continuing operations, attributable to the company, as reported was $1,520.6 million compared to $1,447.7 million for the same period a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $1,857.1 million compared to $1,668.3 million for the same period a year ago. Net cash flow provided by operating activities was $2,924.4 million. Diluted EPS from continuing operations attributable to the company, adjusted was $1.39 compared to $1.12 for the same period a year ago. Adjusted net income was $1,023.1 million compared to $896.0 million for the same period a year ago. For the full year, the company announced revenues of $100,887.1 million compared to $104,098.8 million for the same period a year ago. Operating income was $3,602.4 million compared to $3,551.7 million for the same period a year ago. Income before income taxes was $3,066.2 million compared to $3,030.3 million for the same period a year ago. Net income from continuing operations was $2,035.0 million compared to $1,926.3 million for the same period a year ago. Net income was $2,035.0 million compared to $1,872.7 million for the same period a year ago. Net income attributable to the company was $2,007.6 million compared to $1,844.6 million for the same period a year ago. Diluted earnings per share from continuing operations attributable to the company were $2.64 compared to $2.31 for the same period a year ago. Diluted net earnings attributable to the company were $2.64 compared to $2.25 for the same period a year ago. Net cash flows provided by operating activities was $4,549.0 million compared to $4,757.5 million for the same period a year ago. Purchases of property and equipment were $436.6 million compared to $423.0 million for the same period a year ago. EBITDA from continuing operations, attributable to the company, as reported was $5,817.9 million compared to $5,970.6 million for the same period a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $6,802.5 million compared to $6,664.2 million for the same period a year ago. Diluted EPS from continuing operations attributable to the company, adjusted was $4.88 compared to $4.33 for the same period a year ago. Adjusted net income was $3,704.2 million compared to $3,554.4 million for the same period a year ago. The company provided earnings guidance for the first quarter and full year for the fiscal year ending December 31, 2015. For the first quarter of 2015, the company guided for earnings of $1.07 to $1.11. As expected, this is a sequential decline from fourth quarter that represents growth over first quarter 2014 of 8% to 12%. The company anticipates the quarterly progression of EPS growth in 2015 will be similar to 2014. For the full year, the company expects to announce adjusted earnings per diluted share attributable to the company in the range of $5.35 to $5.49, depreciation between $420 million and $460 million, effective income tax rate between 37.3% and 37.7%, adjusted EBITDA between $6,925 million and $7,125 million, cash flow from operations between $4,500 million and $5,000 million, capital expenditures between $300 million and $400 million. Adjusted EPS will exclude amortization of intangible assets per diluted share expected in the range of $1.51 to $1.55. The company anticipates achieving adjusted earnings per diluted share for 2015 in the range of $5.35 to $5.49, representing growth of 10% to 13% over 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $84.28 USD -0.55

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anthem Inc $146.85 USD +0.30
Cardinal Health Inc $88.95 USD -0.08
McKesson Corp $229.20 USD +1.53
Kroger Co/The $74.31 USD +4.66
Walgreens Boots Alliance Inc $83.20 USD +0.18
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
Price/Earnings 32.1x
Price/Sales 0.6x
Price/Book 3.1x
Price/Cash Flow 30.7x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit www.express-scripts.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.